|
USA-OH-NEWARK Azienda Directories
|
Azienda News:
- Anne Wojcicki’s nonprofit wins bid to acquire genetic testing . . .
23andMe, which at one point was valued at $6 billion, has collected genetic data from 15 million customers through at-home DNA testing kits that used saliva samples
- 23andMe sold in bankruptcy: What it means for your DNA data
Biotech giant Regeneron announced Monday that it would acquire DNA testing company 23andMe for $256 million following a bankruptcy auction The deal includes access to 23andMe's massive
- Bankrupt 23andMe Just Sold Off All Your DNA Data - Futurism
American biotech company Regeneron Pharmaceuticals announced today that it's buying 23andMe, the bankrupt consumer-genomics company that sold take-home DNA kits Regeneron is to pay $256 million
- 23andMe Has Found a Buyer—Here’s What Might Happen to Its . . .
Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy standards
- 23andMe bought by Regeneron in court auction - Engadget
It has been nearly two months since 23andMe declared bankruptcy and the company has officially been sold The US biotech company Regeneron has agreed to buy 23andMe and all of its
- Anne Wojcicki’s nonprofit reaches deal to acquire 23andMe
Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research Institute, a nonprofit led by the company's co-founder and former CEO
- Anne Wojcicki to buy back 23andMe and its data for $305 million
Anne Wojcicki to buy back 23andMe and its data for $305 million
- 23andMe sells gene-testing business to DNA drug maker . . .
Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million
- 23andMe Sold To Biotechnology Company For $256 Million
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection In March 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan
- 23andMe (and Your Genetic Data) Sold to Regeneron in . . .
The company and nearly all of its assets, including its biobank of customer genetic samples, have been purchased by American biotechnology company Regeneron Pharmaceuticals for a cool $256
|
|